In recent developments, semaglutide and liraglutide, which are both recognized as glucagon-like peptide-1 receptor analogs (GLP-1RA) and authorized for managing diabetes and obesity, have demonstrated efficacy in not only causing notable weight loss but also in reducing several obesity-related comorbidities [72,73]. The gene discussed is GLP1R; the disease is diabetes mellitus.